Cell-mediated immunity

NexImmune Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, May 27, 2021

GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB).
  • Long Professor of Immunobiology and of Medicine (Endocrinology), Yale University; Deputy Director, Yale Center for Clinical Investigation; Co-Director, Yale Diabetes Center.
  • Jonathan Schneck, MD, PhD, Professor, Department of Pathology, Medicine and Oncology, The Johns Hopkins University School of Medicine; Director, The Johns Hopkins Translational ImmunoEngineering Center; Co-founder NexImmune.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.

Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity

Retrieved on: 
Monday, February 8, 2021

TNX-2100 is designed to measure T cell immunity to CoV-2.

Key Points: 
  • TNX-2100 is designed to measure T cell immunity to CoV-2.
  • There currently is no standardized laboratory test available to measure T cell immune responses to CoV-2.
  • In the planned clinical protocol for testing TNX-2100, positive skin test controls will be used to confirm that study participants have intact T cell immunity and are not immunodeficient.
  • Induration above a threshold level would signify a positive result and the diameter of the induration would indicate the amount of T cell immunity to the test peptides.

Therapeutic Solutions International Reports QuadraMune™ Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity

Retrieved on: 
Tuesday, January 5, 2021

T cytotoxic cells are a component of the immune system which selectively kills virally infected cells.

Key Points: 
  • T cytotoxic cells are a component of the immune system which selectively kills virally infected cells.
  • "Last week we reported data that QuadraMune increases Th1 cell activity, which orchestrates antiviral immunity.
  • The T cytotoxic cell being the actual effector cells of adaptive antiviral immunity," said Dr. James Veltmeyer, Chief Medical Officer of the Company.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

DGAP-News: CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

Retrieved on: 
Friday, October 23, 2020

CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

Key Points: 
  • CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • The vaccine candidate elicited balanced humoral and cellular immune responses, featuring high antibody titers and very good T cell activation.
  • In addition to the positive immune response, the vaccine candidate induced favorable Th1 cytokine levels.
  • The full manuscript of the preclinical data is available on the pre-print server bioRxiv and was submitted for potential publication in a peer-reviewed journal.

ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins

Retrieved on: 
Monday, August 3, 2020

The results were published in bioRxiv ( A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T Cell and Neutralizing Antibody Responses ).

Key Points: 
  • The results were published in bioRxiv ( A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T Cell and Neutralizing Antibody Responses ).
  • The preclinical study showed that the bivalent hAd5 vaccine resulted in robust T cell and humoral immune responses against SARS-CoV-2 S and N antigens.
  • Immune responses measured on Day 28 showed that the vaccinations elicited robust T cell responses to SARS-CoV-2.
  • We believe this is the first human adenovirus vaccine candidate to use S and N constructs to generate both T cell and humoral responses.

OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon

Retrieved on: 
Monday, July 13, 2020

You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...

Key Points: 
  • You can watch the full episode and read the article here: https://www.kgw.com/article/entertainment/television/programs/straight-t...
    OncoSec and researchers at Providence Cancer Institute previously announced a collaboration to conduct a first-in-human trial of OncoSec's CORVax12 vaccine candidate.
  • CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.
  • Researchers believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
  • OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions.

Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

Retrieved on: 
Tuesday, June 23, 2020

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.

Key Points: 
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins.
  • These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
  • To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus

Retrieved on: 
Thursday, June 11, 2020

T cells are the adaptive immune system's first responders to detect any virus.

Key Points: 
  • T cells are the adaptive immune system's first responders to detect any virus.
  • An in-depth understanding of the T cell response to the COVID-19 virus has a variety of different applications.
  • As Adaptive generates these data, subsequent updates to ImmuneCODE will provide an increasingly clearer picture of the immune response to the COVID-19 virus.
  • ImmuneCODE is an open database that provides a detailed population-level view into the adaptive immune response to the COVID-19 virus.

Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19

Retrieved on: 
Tuesday, May 19, 2020

This kit is for research use only and launched under the T-SPOT Discovery brand.

Key Points: 
  • This kit is for research use only and launched under the T-SPOT Discovery brand.
  • T cell responses develop before antibody generation and can independently provide protection, so studying T cells could give us new insights into immunity to COVID-19.
  • Oxford Immunotec CEO, Peter Wrighton-Smith commented, We are really excited about the release of this RUO T-SPOT Discovery product in such an important area for current research.
  • T-SPOT, the Oxford Immunotec logo, T-Cell Select and T-SPOT Discovery are trademarks of Oxford Immunotec Limited.

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

Retrieved on: 
Friday, May 8, 2020

A vaccine approach that elicits a broad and balanced immune response by activating both humoral and cellular immunity has the potential to provide more effective protection.

Key Points: 
  • A vaccine approach that elicits a broad and balanced immune response by activating both humoral and cellular immunity has the potential to provide more effective protection.
  • An important advantage of our self-replicating mRNA vaccine is the potential to activate both of these important components of adaptive immunity and this preclinical LUNAR-COV19 data confirms a robust and balanced immune response.
  • Rodents were immunized with a single intramuscular dose (0.2, 2, and 10 g) of LUNAR-COV19 vaccine.
  • The self-replicating RNA-based therapeutic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens.